Manmohan will visit UAE next month

NEW DELHI: Prime Minister Manmohan Singh will visit the United Arab Emirates (UAE) next month, government sources confirmed on Monday. This will be the first visit by an Indian PM to the Gulf country in 32 years.

The last visit was by Indira Gandhi in 1981. Singh will visit Abu Dhabi en route to Durban, where is scheduled to attend the BRICS summit in the fourth week of March.

Government has been contemplating a bilateral investment promotion and protection agreement with the UAE and it is possible that the pact will be signed during Singh's visit. India and the UAE have an annual trade volume of over $ 72 billion dollars.

Singh will also hope to address investor concerns there considering how Abu Dhabi-based telecom major Etisalat was forced to shut operations in India last year after the Supreme Court cancelled 122 telecom licences following the 2G scam. In fact, Etihad Airways, which had almost finalized a deal for picking up a 24% stake in Jet Airways, is now said to be doing a rethink because of what is routinely described by international agencies as unpredictable market conditions in India. According to sources, the UAE is insisting on signing the pact before the Etihad-Jet deal. The UAE is the 10th biggest investor in India in terms of FDI.

``Considering the size of the Indian expatriate community it is high time an Indian prime minister visited UAE,'' said a source confirming that the visit will take place just after the first part of the budget session.

The Indian expatriate community is the largest in the UAE, totaling around 2 million. According to foreign ministry data, about 20% of the community comprises professionally qualified personnel, another 20% are white-collar non-professionals and the rest are blue-collar workers. The presence of a large number of blue-collar workers has also forced India to develop effective grievance-redressal mechanisms for its workers. Then President Pratibha Patil had visited the UAE in 2010 during which the Gulf nation reaffirmed support for India's permanent membership in an expanded UN Security Council.

Read More..

Mediterranean-style diets found to cut heart risks


Pour on the olive oil, preferably over fish and vegetables: One of the longest and most scientific tests of a Mediterranean diet suggests this style of eating can cut the chance of suffering heart-related problems, especially strokes, in older people at high risk of them.


The study lasted five years and involved about 7,500 people in Spain. Those who ate Mediterranean-style with lots of olive oil or nuts had a 30 percent lower risk of major cardiovascular problems compared to those who were told to follow a low-fat diet but who in reality, didn't cut fat very much. Mediterranean meant lots of fruit, fish, chicken, beans, tomato sauce, salads, and wine and little baked goods and pastries.


Mediterranean diets have long been touted as heart-healthy, but that's based on observational studies that can't prove the point. The new research is much stronger because people were assigned diets to follow for a long time and carefully monitored. Doctors even did lab tests to verify that the Mediterranean diet folks were consuming more olive oil or nuts as recommended.


Most of these people were taking medicines for high cholesterol and blood pressure, and researchers did not alter those proven treatments, said one study leader, Dr. Ramon Estruch of Hospital Clinic in Barcelona.


But as a first step to prevent heart problems, "we think diet is better than a drug" because it has few if any side effects, Estruch said. "Diet works."


Results were published online Monday by the New England Journal of Medicine and were discussed at a nutrition conference in Loma Linda, Calif.


People in the study were not given rigid menus or calorie goals because weight loss was not the aim. That could be why they found the "diets" easy to stick with — only about 7 percent dropped out within two years. There were twice as many dropouts in the low-fat group than among those eating Mediterranean-style.


Researchers also provided the nuts and olive oil, so it didn't cost participants anything to use these relatively pricey ingredients. The type of oil may have mattered — they used extra-virgin olive oil, which is minimally processed and richer than regular or light olive oil in the chemicals and nutrients that earlier studies have suggested are beneficial.


The study involved people ages 55 to 80, just over half of them women. All were free of heart disease at the start but were at high risk for it because of health problems — half had diabetes and most were overweight and had high cholesterol and blood pressure.


They were assigned to one of three groups: Two followed a Mediterranean diet supplemented with either extra-virgin olive oil (4 tablespoons a day) or with walnuts, hazelnuts and almonds (a fistful a day). The third group was urged to eat a low-fat diet heavy on bread, potatoes, pasta, rice, fruits, vegetables and fish and light on baked goods, nuts, oils and red meat.


Independent monitors stopped the study after nearly five years when they saw fewer problems in the two groups on Mediterranean diets.


Doctors tracked a composite of heart attacks, strokes or heart-related deaths. There were 96 of these in the Mediterranean-olive oil group, 83 in the Mediterranean-nut group and 109 in the low-fat group.


Looked at individually, stroke was the only problem where type of diet made a big difference. Diet had no effect on death rates overall.


The Mediterranean diet proved better even though its followers ate about 200 calories more per day than the low-fat group did. The study leaders now are analyzing how each of the diets affected weight gain or loss and body mass index.


The Spanish government's health research agency initiated and paid for the study, and foods were supplied by olive oil and nut producers in Spain and the California Walnut Commission. Many of the authors have extensive financial ties to food, wine and other industry groups but said the sponsors had no role in designing the study or analyzing and reporting its results.


Rachel Johnson, a University of Vermont professor who heads the American Heart Association's nutrition committee, said the study is very strong because of the lab tests to verify oil and nut consumption and because researchers tracked actual heart attacks, strokes and deaths — not just changes in risk factors such as high cholesterol.


"At the end of the day, what we care about is whether or not disease develops," she said. "It's an important study."


Rena Wing, a weight-loss expert at Brown University, noted that researchers provided the oil and nuts, and said "it's not clear if people could get the same results from self-designed Mediterranean diets" — or if Americans would stick to them more than Europeans who are used to such foods.


Dr. George Bray of the Pennington Biomedical Research Center in Baton Rouge, La., said he would give the study "a positive — even glowing — comment" and called it "the best and certainly one of the largest prospective dietary trials ever done."


"The data are sufficiently strong to convince me to move my dietary pattern closer to the Mediterranean Diet that they outline," he added.


Another independent expert also praised the study as evidence diet can lower heart risks.


"The risk reduction is close to that achieved with statins," cholesterol-lowering drugs, said Dr. Robert Eckel, a diet and heart disease expert at the University of Colorado.


"But this study was not carried out or intended to compare diet to statins or blood pressure medicines," he warned. "I don't think people should think now they can quit taking their medicines."


___


Online:


Journal: http://www.nejm.org


___


Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP


Read More..

Pistorius' Brother Facing Own Homicide Trial












The attorney for Oscar Pistorius' family said today that the Olympian's brother is facing a culpable homicide charge relating to a 2008 road accident in which a motorcyclist was killed.


Carl Pistorius, who sat behind his younger brother, Oscar, every day at his bail hearing, will now face his own homicide trial for the accident five years ago, which his attorney, Kenny Oldwage, said he "deeply regrets."


Carl Pistorius is charged with culpable homicide, which refers to the unlawful negligent killing of another person. The charges were initially dropped, but were later reinstated, Oldwage said in a statement.


Full Coverage: Oscar Pistorius Case


Pistorius quietly appeared in court on Thursday, one day before his Paralympic gold-medalist brother was released on bail, Oldwage said. His next appearance is scheduled for the end of March.






Liza van Deventer/Foto24/Gallo Images/Getty Images











'Blade Runner' Murder Charges: Oscar Pistorius Out on Bail Watch Video











Oscar Pistorius Granted Bail in Murder Case Watch Video





It was the latest twist in a case that has drawn international attention, after 26-year-old Oscar Pistorius, a double amputee who ran in both the 2012 Olympic and Paralympic games, was charged with the premeditated murder of his model girlfriend, Reeva Steenkamp.


On Saturday, Carl Pistorius' Twitter handle was hacked, according to a family spokeswoman, prompting the Pistorius family to cancel their social media accounts.


Steenkamp's parents speak about the Valentine's Day shooting that ended their daughter's life in a sit-down interview on South African television tonight.


On Saturday, the model's father, Barry Steenkamp, told the Afrikaans-language Beeld newspaper that Pistorius will have to "live with his conscience" and will "suffer" if his story that he shot Steenkamp because he believed she was an intruder is false.


RELATED: Oscar Pistorius Case: Key Elements to the Murder Investigation


After a four-day long bail hearing, Pistorius was granted bail Friday by a South African magistrate.


The court set bail at about $113,000 (1 million rand) and June 4 as the date for Pistorius' next court appearance.


Pistoriuis is believed to be staying at his uncle's house as he awaits trial. As part of his bail conditions, Pistorius must give up all his guns, he cannot drink alcohol or return to the home where the shooting occurred, and he must check in with a police department twice a week.



Read More..

China's Huawei claims world's fastest smartphone






BARCELONA: China's Huawei, the number three smartphone maker behind giants Samsung and Apple, unveiled Sunday a new mobile, the Ascend P2, which it claims is the fastest in the world.

Sharp-cornered and thinner than a pencil at 8.4 mm, the company said it can achieve speeds of 150 Mbps, fast enough to download a two-hour high-definition movie in less than five minutes.

The mobile, which has a 4.7-inch, high definition screen, has a powerful 1.5 GHz quad-core processor and is able to use the fourth-generation high speed mobile networks being rolled out worldwide.

Unveiling the device on the eve of the opening Monday of the four-day Mobile World Congress in Barcelona, Spain, the company said it was "the world's fastest smartphone," smashing all previous records.

Huawei said its phone surpassed top speeds of 100 Mbps for the fourth-generation network ready versions of Apple's flagship iPhone 5 and Samsung's Galaxy SIII.

The Ascend P2 will launch in France through Orange in June and is also expected to be available worldwide during the second quarter of 2013, it said.

"Ascend P2 downloads HD movies in minutes, and loads online videos, web pages, songs or e-Books in seconds," Huawei said in a company statement issued at the launch.

The phone, which includes a 13 megapixel camera, is the latest shot in Huawei's battle against the fast-growing market's titans Samsung and Apple.

Samsung and Apple accounted for more than half of all smartphone sales in the final quarter of 2012 -- 29.0 per cent for Samsung and 22.1 per cent for Apple -- according to research firm Strategy Analytics.

Behind Samsung and Apple, however, Chinese firms held the third, fourth and fifth spots -- with 5.3 per cent for Huawei, 4.7 per cent for ZTE and 4.4 per cent for Lenovo.

- AFP/jc



Read More..

Karunanidhi slams AIADMK, BJP over stand on Sethusamudram

CHENNAI: DMK Chief M Karunanidhi on Sunday called on the Centre to take steps to present a strong case before the Supreme Court on the Sethusamundram shipping channel project sought to be blocked by "communal forces".

Flaying the BJP and the AIADMK for their stand on the project, Karunanidhi said the national party, while in power, had proposed the alignment for the project which involved dredging of 'Ram Sethu', the mythical bridge believed to have been built by Lord Ram to cross over to Lanka. Now it is firmly opposed to the project.

"After considering various proposals over the route, the Vajpayee-led NDA government had decided to implement the project on alignment No 6 which involves the Ram Sethu, called Adam's Bridge. Forgetting that, it is now opposing dredging of Ram Sethu," he said.

The Pachauri Committee has said the shipping channel project is not viable on economic and ecological grounds. The government has rejected the report and maintained that it intends to pursue the project which will cut through the Adam's Bridge.

On the AIADMK chief J Jayalalithaa's demand to the prime minister that Ram Sethu be declared a national monument, Karunanidhi said she had claimed in 2005 that it was due to her efforts that preliminary work on the project was initiated in 1998 and that she had been instrumental in its taking shape.

The AIADMK had in its 2001 poll manifesto spoken in favour of the Sethusamudram project, he said, adding she had turned against it since she didn't want DMK to take the credit.

"Some communal forces had taken the issue to the apex court with a view to creating roadblocks," he said.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Jessica Ridgeway Murder Suspect to Stand Trial












The teenage suspect in the murder and dismemberment of 10-year-old Jessica Ridgeway will stand trial after a judge ruled there is enough evidence, including an alleged 911 confession, to move forward with the case.


Prosecutors played the 911 recording on Friday at a preliminary hearing for Austin Sigg, 18, in which the teen confessed to murdering the fifth grader and trying to kidnap a female jogger.


"I murdered Jessica Ridgeway, I have proof that I did. I'm giving myself up completely, there will be no resistance whatsoever," Sigg said on the Oct. 23, 2012, recording, according to ABC News Denver affiliate KMGH-TV.


The dispatcher then asked about his criminal history.


"The only other [incident] was Ketner Lake, where a woman was attacked. That was me," Sigg said in the recording.


A lead investigator on the case testified that Mindy Sigg, the teen's mother, told the dispatcher her son had hidden Jessica's remains in a crawl space under the family home, KMGH reported.


Authorities arrested Sigg at his Westminster, Colo., home that evening.


Sigg is charged with murder, kidnapping, sexual assault and robbery in the Ridgeway case.


He faces an attempted kidnapping charge for the May 28, 2012, attack on a 22-year-old female jogger. Police said a man tried to grab her from behind on a trail around Ketner Lake.






Courtesy Westminster Police Department











Jessica Ridgeway's Death Connected to Jogger Attack Watch Video









Jessica Ridgeway Abduction Case: Hunt For Child Predator Watch Video









Missing Colorado Girl Jessica Ridgeway: Finding a Killer Watch Video





The woman said the man tried to put a rag over her mouth that had a chemical smell. She was able to get away and call 911.


A judge ruled Friday that Sigg should be held without bail. He is scheduled to be arraigned March 12.


Jessica Ridgeway Disappearance Rattles Community


The search last fall for Jessica Ridgeway had the Westminster, Colo., community on edge as they grappled with the notion a cold-blooded predator could be hiding in their midst.


The fifth-grader was last seen on Oct. 5, 2012, when she left for school. She never showed up at a nearby park where she was supposed to meet friends for the one-mile walk to her elementary school. It was a route she took every day, but this time she never arrived.


An extensive FBI search included knocking on doors, road blocks, and encouraging people to report any suspicious behavior observed in friends and family members.


Jessica's dismembered torso was found inside a bag in Arvada, Colo., on Oct. 10. Her legs, arms and head were found in the crawl space under Sigg's home, Detective Luis Lopez told the court on Friday, according to KMGH. Her cause of death was asphyxiation, he said.


Authorities turned their attention to Sigg after a neighbor called a tip line Oct. 19 to report Sigg wore a cross similar to the one police believed the killer wore, and said the teen had a fascination with death. Two FBI agents took a DNA sample from Sigg, who was 17 years old at the time.


It wasn't until the 911 call on Oct. 23 that Sigg was taken into custody.


Sigg had been a student at Arapahoe Community College in Littleton, Colo., according to his arrest report, where classmates said he was studying mortuary science.


The Ridgeway and Sigg families attended the hearing on Friday. Both families were dressed in purple, which was Jessica's favorite color.


ABC News' Christina Ng contributed to this report.



Read More..

Egypt's ElBaradei urges election boycott






CAIRO: Opposition leader Mohamed ElBaradei on Saturday called for a boycott of Egypt's upcoming legislative elections, as the president rescheduled the first round after Copts complained it would clash with a Christian holiday.

"Called for parliamentary election boycott in 2010 to expose sham democracy. Today I repeat my call, will not be part of an act of deception," the Nobel Peace laureate and former head of the UN atomic watchdog wrote on Twitter.

Former foreign minister Amr Mussa, another leader in the National Salvation Front (NSF), said many members of the opposition bloc were inclined to boycott the four-round election, but a final position had not yet been taken.

"There is a large group that wants a boycott, but it has not yet been discussed, and no decision has been taken," he told AFP.

Initially the election had been set to begin on April 27, with a new parliament to convene on July 6.

But the dates conflicted with pre-Easter and Easter holidays, prompting Islamist President Mohamed Morsi to announce new ones "in response to requests by Christian brothers," a reference to the Coptic Church, his office said Saturday.

A statement said the new starting date for the election would be April 22-23 instead of 27-28 which fell on the Christian holidays of Lazarus Saturday and Palm Sunday.

The second round will take place on April 29-30 instead of May 4-5, to avoid interference with Easter weekend, the statement said, adding that as a result of the changes parliament was now set to convene on July 2, instead of July 6.

Earlier Father Rafiq Greish, the Catholic Church's spokesman in Egypt, told AFP that he spoke with the presidency, which "accepted" rescheduling the first round.

Many Copts fear that Morsi and his Islamist allies seek to marginalise the minority community which represents six to 10 per cent of Egypt's 83-million population of mostly Sunni Muslims.

ElBaradei, who did not elaborate about his boycott call on Twitter, raised suspicion that the vote might be rigged, as was the case in a 2010 election under ousted long-time president Hosni Mubarak.

Leaders of the NSF, an alliance that brings together liberal and secular leaning groups, have previously proposed a postponement of the vote.

The coalition organised massive protests against Morsi in November and December after he adopted now-repealed powers that shielded his decisions from judicial review.

But anti-Morsi protests have slowed since he pushed through an Islamist-drafted constitution in a December referendum, with the mass rallies giving way to smaller, and often violent, protests.

The opposition, less organised than Morsi's Muslim Brotherhood, has insisted the president appoint a new government before the election while the presidency says the new parliament should have the right to appoint the cabinet.

The Brotherhood and Islamist allies dominated the last parliamentary election in 2011 that resulted in an Islamist-majority house which a court annulled on a technicality before Morsi's election last June.

But due to increased anti-Morsi sentiment, Hamdeen Sabahi, another NSF leader, has said the opposition coalition could now win up to 50 per cent of seats in parliament if it chose to contest the election.

- AFP/jc



Read More..

Hyderabad blasts: Local outfit under police’s scanner

HYDERABAD: With no breakthrough so far in Dilsukhnagar serial blasts that claimed 17 lives and left nearly 150 injured, the investigating agencies are scanning the activities of Dursgah-e-Jihad-o-Shahadat (DJS), a city-based outfit whose members were alleged to have been involved in a series of terror attacks in the past.

"DJS has been a training ground for militants in the past. Many of them had developed links with foreign intelligence agencies and terrorist organisations and carried out attacks in Hyderabad and elsewhere. It is critical to know the status of these members in the context of the latest blasts," a police officer said on condition of anonymity.

Local police sources said the outfit lost its sheen after the death of its founder Shaikh Mahboob Ali in 2011. The new DJS president Mohammed Abdul Majid, son-in-law of the founder, staged a protest on December 6, the anniversary of Babri Masjid demolition. He also organised protests against a police officer in October for which he was behind bars for over two weeks.

Police sources said IM operative Syed Maqbool, who was arrested by the Delhi police in October last year for planning terror attacks across the country, was once linked to DJS. Mohammed Abdul Shahid Bilal and his brother Samad, who were first linked with Mecca Masjid bomb blast and later killed in Karachi, were also DJS members. Mohammed Viquar, who reportedly killed two policemen in 2009 and 2010 had his initial training with DJS. Another militant Ghulam Yazdani, who was killed in a police encounter in Delhi, also owed allegiance to the outfit.

The founder's grandson Nijihullah was packed off to Saudi Arabia to escape police, but later fell into the hands of Pakistani terror handlers. He was reportedly trained in Pakistan and later pushed back into India. His present whereabouts are not known.

Denying any role in terror activities, DJS President Abdul Majid had earlier claimed that the outfit had trained about 50,000 youths in self-defence in the past. The two camps of DJS where "self-defence training" was imparted—Ujale Shah Eidgah grounds and Purani Haveli—are now defunct.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..